Real-world data reveals long-term survival in advanced liver cancer patients on lenvatinib
NCT ID NCT07298538
First seen Jan 07, 2026 · Last updated May 24, 2026 · Updated 22 times
Summary
This study looked back at medical records from 800 adults with unresectable hepatocellular carcinoma (a type of liver cancer that cannot be removed by surgery) who were treated with lenvatinib-based therapy at six hospitals. The goal was to see how long patients lived and how well the treatment worked in everyday practice, not just in a controlled trial. The findings help doctors understand the real-world benefits and risks of this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, 300060, China
Conditions
Explore the condition pages connected to this study.